doxepin
Commercial- Indications
- Insomnia
Company intelligence / Profile preview
Hawthorn Pharmaceuticals was a commercial-stage specialty pharmaceutical company focused on developing and marketing prescription drugs across multiple therapeutic areas. Its lead commercial product was Granisol™ oral solution for chemotherapy/radiation-induced nausea and vomiting. The company had an active development pipeline including NDAs in various stages and at least one investigational drug ("haw AD14") targeting Alzheimer’s disease that had not yet reached approval as of the last available data. The company was acquired by Pernix Therapeutics in early 2013 and subsequently ceased independent operations[5][10].
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hawthorn Pharmaceuticals, Inc..